Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

NCT04819399 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG: Catumaxomab

Sponsor

Lindis Biotech GmbH